311,327 Shares in Abbott Laboratories $ABT Bought by Rakuten Investment Management Inc.

Posted by Geri Gentry on Nov 4th, 2026

Rakuten Investment Management Inc. acquired a new stake in Abbott Laboratories (NYSE:ABT – Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 311,327 shares of the healthcare product maker’s stock, valued at approximately $31,428,000.

Several other institutional investors have also added to or reduced their stakes in ABT. Elwood & Goetz Wealth Advisory Group LLC increased its holdings in shares of Abbott Laboratories by 3.1% in the 3rd quarter. Elwood & Goetz Wealth Advisory Group LLC now owns 3,216 shares of the healthcare product maker’s stock worth $318,000 after purchasing an additional 97 shares in the last quarter. Parkway Wealth Management Group LLC lifted its holdings in shares of Abbott Laboratories by 3.2% during the third quarter. Parkway Wealth Management Group LLC now owns 3,208 shares of the healthcare product maker’s stock valued at $317,000 after purchasing an additional 98 shares in the last quarter. Signature Equity Partners LLC lifted its holdings in shares of Abbott Laboratories by 7.9% during the third quarter. Signature Equity Partners LLC now owns 1,363 shares of the healthcare product maker’s stock valued at $135,000 after purchasing an additional 100 shares in the last quarter. St. Johns Investment Management Company LLC lifted its holdings in shares of Abbott Laboratories by 1.0% during the second quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker’s stock valued at $895,000 after purchasing an additional 101 shares in the last quarter. Finally, AA Financial Advisors LLC boosted its position in shares of Abbott Laboratories by 1.7% during the third quarter. AA Financial Advisors LLC now owns 6,186 shares of the healthcare product maker’s stock valued at $611,000 after buying an additional 101 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on ABT shares. Robert W. Baird lifted their price objective on Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a report on Thursday, October 22nd. Barclays initiated coverage on shares of Abbott Laboratories in a research note on Wednesday, October 7th. They set an “overweight” rating and a $120.00 target price on the stock. Weiss Ratings raised shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 18th. Wall Street Zen raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, October 24th. Finally, Rothschild & Co Redburn upgraded shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $119.00 to $127.00 in a research note on Friday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $118.32.

Check Out Our Latest Research Report on ABT

Abbott Laboratories Price Performance

NYSE ABT opened at $109.43 on Wednesday. The business’s fifty day moving average price is $104.09 and its 200-day moving average price is $101.91. The stock has a market capitalization of $189.35 billion, a price-to-earnings ratio of 40.83, a PEG ratio of 1.93 and a beta of 0.54. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $132.02.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The firm had revenue of $13.01 billion for the quarter, compared to the consensus estimate of $12.99 billion. During the same period last year, the business posted $1.30 EPS. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. On average, equities analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 94.03%.

Abbott Laboratories Company Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.